Upjohn's Ansaid
Executive Summary
Patent for flurbiprofen expired Feb. 19; firm has not sought legislative extension this year, as it did in the last Congress. A bill reviving an expired patent would be unprecedented. Another option for Upjohn to pursue is asking a legislator to insert into appropriate FDA legislation an administrative provision for market exclusivity.